Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Zevra Therapeutics (ZVRA) over the last 11 years, with Q3 2025 value amounting to $11.1 million.

  • Zevra Therapeutics' Accounts Payables fell 5474.17% to $11.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.1 million, marking a year-over-year decrease of 5474.17%. This contributed to the annual value of $25.5 million for FY2024, which is 1037.57% down from last year.
  • Zevra Therapeutics' Accounts Payables amounted to $11.1 million in Q3 2025, which was down 5474.17% from $15.8 million recorded in Q2 2025.
  • In the past 5 years, Zevra Therapeutics' Accounts Payables registered a high of $28.4 million during Q4 2023, and its lowest value of $2.1 million during Q3 2021.
  • Moreover, its 5-year median value for Accounts Payables was $10.5 million (2023), whereas its average is $12.0 million.
  • Its Accounts Payables has fluctuated over the past 5 years, first tumbled by 5549.49% in 2021, then skyrocketed by 36041.5% in 2023.
  • Zevra Therapeutics' Accounts Payables (Quarter) stood at $3.0 million in 2021, then skyrocketed by 103.06% to $6.2 million in 2022, then skyrocketed by 360.41% to $28.4 million in 2023, then fell by 10.38% to $25.5 million in 2024, then crashed by 56.51% to $11.1 million in 2025.
  • Its Accounts Payables was $11.1 million in Q3 2025, compared to $15.8 million in Q2 2025 and $17.8 million in Q1 2025.